What empiric antimicrobial therapy should be given when both fungal infection and gram‑negative bacilli are suspected?

Empiric Therapy for Suspected Fungal and Gram-Negative Bacilli Co-Infection

When both fungal infection and gram-negative bacilli are suspected, use combination therapy with an echinocandin (caspofungin 70 mg loading dose then 50 mg daily, anidulafungin 200 mg loading then 100 mg daily, or micafungin 100 mg daily) PLUS an anti-pseudomonal beta-lactam with appropriate gram-negative coverage based on local resistance patterns.

Rationale and Clinical Approach

This dual-pathogen scenario most commonly occurs in critically ill ICU patients, particularly those with neutropenia, septic shock, or multiple risk factors for invasive candidiasis. The therapeutic strategy must address both threats simultaneously without delay.

Antifungal Component

For the fungal coverage, echinocandins are the preferred empiric choice in critically ill patients with suspected invasive candidiasis 1. The IDSA 2016 Candidiasis Guidelines provide strong to moderate evidence that empiric antifungal therapy should be initiated immediately in patients with:

• Clinical signs of septic shock
• Risk factors for invasive candidiasis
• No other identified fever source

Fluconazole (800 mg loading dose, then 400 mg daily) is an alternative but only in settings with low rates (<5%) of fluconazole-resistant Candida and in patients not previously on azole prophylaxis 1. Given the severity implied by concurrent gram-negative suspicion, echinocandins provide broader coverage including azole-resistant species.

Antibacterial Component

For gram-negative coverage, the choice depends on your clinical context:

In febrile neutropenia or severe sepsis: Use a broad-spectrum anti-pseudomonal beta-lactam as the backbone. Contemporary evidence shows that early mortality in neutropenic patients correlates with inadequate gram-negative coverage, not gram-positive gaps 2. The default should be rapid initiation of locally-informed anti-pseudomonal therapy.

In carbapenem-resistant gram-negative bacilli (CRGNB) settings: Consider newer agents like ceftazidime-avibactam, ceftolozane-tazobactam, imipenem-relebactam, or meropenem-vaborbactam based on local susceptibility patterns 3. MIC testing should be performed where possible to guide definitive therapy, though empiric treatment must not be delayed 3.

Key Clinical Pitfalls

• Do not delay empiric therapy while awaiting cultures or MIC results—start both antifungal and antibacterial coverage immediately in septic shock 1
• Avoid fluconazole monotherapy in critically ill patients or those with prior azole exposure—resistance is increasingly common 1
• Do not add empiric vancomycin unless there are specific indicators of resistant gram-positive infection (MRSA-positive screening, catheter-related infection, skin/soft tissue source)—mortality in these scenarios is driven by gram-negative pathogens 2
• Lipid formulation amphotericin B (3-5 mg/kg daily) is an alternative to echinocandins but has more toxicity concerns 1

Duration and De-escalation

Continue combination therapy until:

• Cultures identify specific pathogens, allowing targeted therapy
• Clinical improvement occurs with resolution of shock
• At least 2 weeks after documented bloodstream clearance for candidemia 1

Source control is critical: Remove central venous catheters when candidemia is documented (strong recommendation) 1. For neutropenic patients, catheter removal should be individualized as GI sources predominate 1.